Logo

Alnylam Wraps Up Enrollment in RSV Drug Trial

Dec 01, 2011
Premium

Alnylam Pharmaceuticals announced this week that it has completed enrollment in a phase IIb study of its investigational respiratory syncytial virus therapy ALN-RSV01.

The trial is a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients, according to the company. It is being conducted at lung-transplant centers in six countries. As previously disclosed, data are expected to be reported mid-2012 (GSN 11/3/2011).

Filed under

Gene Editing, Gene Silencing, & CRISPR
Infectious Disease
RSV
RNAi
Alnylam
Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.